UK-based immuno-oncology developer Igem Therapeutics achieved a first close of its series A round at £2m ($2.5m) today, supplied by early-stage life science venture capital firm Epidarex Capital.
The company is in the process of identifying other investors for the round’s final close, though it has not revealed a target size.
Igem Therapeutics is based on research by Sophia Karagiannis of King’s College London (KCL). The company is working on a pipeline of antibody candidates that can destroy solid tumours.
…
